Technical Analysis for DMAC - DiaMedica Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.33% | |
| Wide Bands | Range Expansion | -0.33% | |
| 180 Bullish Setup | Bullish Swing Setup | -5.64% | |
| Wide Bands | Range Expansion | -5.64% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Up 2% | about 15 hours ago |
| Possible NR7 | about 15 hours ago |
| Possible Inside Day | about 15 hours ago |
| Up 1% | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.75 |
| 52 Week Low | 1.67 |
| Average Volume | 44,004 |
| 200-Day Moving Average | 2.76 |
| 50-Day Moving Average | 2.80 |
| 20-Day Moving Average | 2.85 |
| 10-Day Moving Average | 3.19 |
| Average True Range | 0.23 |
| RSI (14) | 53.05 |
| ADX | 18.08 |
| +DI | 26.46 |
| -DI | 21.34 |
| Chandelier Exit (Long, 3 ATRs) | 3.04 |
| Chandelier Exit (Short, 3 ATRs) | 2.95 |
| Upper Bollinger Bands | 3.64 |
| Lower Bollinger Band | 2.05 |
| Percent B (%b) | 0.6 |
| BandWidth | 55.84 |
| MACD Line | 0.14 |
| MACD Signal Line | 0.11 |
| MACD Histogram | 0.0228 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.18 | ||||
| Resistance 3 (R3) | 3.19 | 3.15 | 3.15 | ||
| Resistance 2 (R2) | 3.15 | 3.11 | 3.14 | 3.14 | |
| Resistance 1 (R1) | 3.08 | 3.08 | 3.06 | 3.07 | 3.13 |
| Pivot Point | 3.04 | 3.04 | 3.03 | 3.03 | 3.04 |
| Support 1 (S1) | 2.97 | 3.00 | 2.95 | 2.96 | 2.89 |
| Support 2 (S2) | 2.93 | 2.97 | 2.92 | 2.88 | |
| Support 3 (S3) | 2.86 | 2.93 | 2.87 | ||
| Support 4 (S4) | 2.85 |
